Biomarker analysis with next generation sequencer in pulmonary sarcomatoid carcinomas

• Project/Area Number: 15K09164
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory organ internal medicine
• Research Institution: Hokkaido University
• Principal Investigator: OIZUMI SATOSHI 北海道大学, 医学研究院, 客員研究員 (10421968)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000); Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
• Keywords: 肺肉腫様癌 / 肺肉腫様 / ドライバー遺伝子 / 化学療法 / 分子標的治療

Outline of Final Research Achievements

Efficacy of chemotherapy or presence of targetable genomic alterations has remained unclear in pulmonary sarcomatoid carcinomas. Development of therapeutic strategies for this entity is an important issue.
Biomarker analysis is being conducted with next generation sequencer in parallel with our prospective phase 2 study which prospectively examines the efficacy of chemotherapy in pulmonary sarcomatoid carcinomas.
So far 15 patients have been enrolled onto this study (target patient number; 30), and we are conducting the biomarker analysis employing the tissue materials from the enrolled patients.

Research Products

• [Journal Article] Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations. (2018)
  • Author(s): Oizumi S, Sugawara S, Minato K, Harada T, Inoue A, Fujita Y, Maemondo M, Watanabe S, Ito K, Gemma A, Demura Y, Fukumoto S, Isobe H, Kinoshita I, Morita S, Kobayashi K, Hagiwara K, Aiba K, Nukiwa T.
  • Journal Title: ESMO Open Volume: 3(2) Issue: 2 Pages: e000313-e000313
  • DOI: 10.1136/esmoopen-2017-000313
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002) (2017)
  • Author(s): Ikezawa Y, Asahina H, Oizumi S, Watanabe M, Takamura K, Kawai Y, Yamada N, Harada T, Kinoshita I, Fujita Y, Miyauchi E, Ogi T, Amano T, Furuta M, Sakakibara-Konishi J, Nishihara H, Dosaka-Akita H, Isobe H, Nishimura M; Hokkaido Lung Cancer Clinical Study Group
  • Journal Title: Cancer Chemother Pharmacol Volume: 80 Issue: 5 Pages: 955-963
  • DOI: 10.1007/s00280-017-3432-4
  • NAID: 120006533131
  • Peer Reviewed / Int'l Joint Research
• [Journal Article] Immunohistochemical profiling of receptor tyrosine kinases, MED12, and TGF-βRII of surgically resected small cell lung cancer, and the potential of c-kit as a prognostic marker (2016)
  • Author(s): Yokouchi H, Nishihara H, Harada T, Ishida T, Yamazaki S, Kikuchi H, Oizumi S, Uramoto H, Tanaka F, Harada M, Akie K, Sugaya F, Fujita Y, Takamura K, Kojima T, Higuchi M, Honjo O, Minami Y, Watanabe N, Goto A, Suzuki H, Dosaka-Akita H, Isobe H, Nishimura M, Munakata M
  • Journal Title: Oncotarget Volume: Dec 31 Issue: 24 Pages: 39711-39726
  • DOI: 10.18632/oncotarget.14410
  • Peer Reviewed / Open Access
• [Journal Article] rognostic impact of clinical variables on surgically resected small-cell lung cancer: Results of a retrospective multicenter analysis (FIGHT002A and HOT1301A) (2015)
  • Author(s): Yokouchi H, Ishida T, Yamazaki S, Kikuchi H, Oizumi S, Uramoto H, Tanaka F, Harada M, Akie K, Sugaya F, Fujita Y, Fukuhara T, Takamura K, Kojima T, Harada T, Higuchi M, Matsuura Y, Honjo O, Minami Y, Watanabe N, Nishihara H, Suzuki H, Dosaka-Akita H, Isobe H, Nishimura M, Munakata M
  • Journal Title: Lung Cancer Volume: 90 Issue: 3 Pages: 548-53
  • DOI: 10.1016/j.lungcan.2015.10.010
  • Peer Reviewed / Acknowledgement Compliant
• [Journal Article] Factors associated with a poor response to gefitinib in the NEJ002 study: Smoking and the L858R mutation. (2015)
  • Author(s): Fukuhara T, Yoshizawa H et al.
  • Journal Title: Lung Cancer Volume: 88 Issue: 2 Pages: 181-6
  • DOI: 10.1016/j.lungcan.2015.02.004
  • Peer Reviewed / Open Access
• [Journal Article] First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies. (2015)
  • Author(s): Morikawa N, Minegishi Y, Inoue A, Maemondo M, Kobayashi K, Sugawara S, Harada M, Hagiwara K, Okinaga S, Oizumi S, Nukiwa T, Gemma A; North-East Japan Study Group.
  • Journal Title: Expert Opin Pharmacother. Volume: 16(4) Issue: 4 Pages: 465-72
  • DOI: 10.1517/14656566.2015.1002396
  • Peer Reviewed / Open Access
• [Journal Article] Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902. (2015)
  • Author(s): Sugawara S, Oizumi S, Minato K, Harada T, Inoue A, Fujita Y, Maemondo M, Yoshizawa H, Ito K, Gemma A, Nishitsuji M, Harada M, Isobe H, Kinoshita I, Morita S, Kobayashi K, Hagiwara K, Kurihara M, Nukiwa T; North East Japan Study Group and Tokyo Cooperative Oncology Group
  • Journal Title: Ann Oncol. Volume: 26(5) Issue: 5 Pages: 888-94
  • DOI: 10.1093/annonc/mdv063
  • Peer Reviewed / Open Access
• [Journal Article] Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702 (2015)
  • Author(s): .Inoue A, Sugawara S, Maemondo M, Mori Y, Oizumi S, Harada M, Taima K, Morikawa N, Ishida T, Kinoshita I, Watanabe H, Suzuki T, Nakagawa T, Saito R, Nukiwa T
  • Journal Title: Lung Cancer Volume: 89 Issue: 1 Pages: 61-5
  • DOI: 10.1016/j.lungcan.2015.04.012
  • Peer Reviewed
• [Journal Article] Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002) (2015)
  • Author(s): Miyauchi E, Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Saijo Y, Yoshizawa H, Hagiwara K, Nukiwa T; North-East Japan Study Group
  • Journal Title: Jpn J Clin Oncol Volume: 45 Issue: 7 Pages: 670-6
  • DOI: 10.1093/jjco/hyv054
  • Peer Reviewed / Open Access
• [Presentation] Updated survival outcomes of NEJ005/TCOG0902, a randomized phase II study of concurrent (C) versus sequential alternating (S) gefitinib and chemotherapy in previously untreated non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (EGFR) mutations (2017)
  • Author(s): Satoshi Oizumi
  • Organizer: The 53th American Society of Clinical Oncocology Annual Meeting
• [Presentation] Combinational Strategies of EGFR-TKI and Other Agents for EGFR-mutated Non-small Cell Lung Cancer (2016)
  • Author(s): 大泉聡史
  • Organizer: 第57回日本肺癌学会学術集会
  • Place of Presentation: 福岡サンパレス（福岡県福岡）
• [Presentation] EGFR遺伝子変異陽性の非小細胞肺癌におけるEGFR-TKIの併用療法について-さらなる可能性を考える- (2015)
  • Author(s): 大泉聡史
  • Organizer: 第56回日本肺癌学会学術集会
  • Place of Presentation: パシフィコ横浜（神奈川県・横浜市）
  • Year and Date: 2015-11-26